Triazole antifungals

Fluconazole is a triazole antifungal that may be administered in recurrent vaginal candidiasis. Fluconazole interacts with sulphonylureas such as glibenclamide, resulting in increased plasma concentrations of the sulphonylurea. 

Onychomycosis is a fungal nail infection. In severe cases, oral antifungals are recommended as first-line agents. Oral triazole antifungals such as itraconazole (Sporanox capsules) as well as terbinafine (Lamisil tablets) are recommended. Treatment with itraconazole poses a lesser burden to patients... 

Itraconazole is a triazole antifungal, which increases the plasma concentration of digoxin, hence increasing the risk of digoxin toxicity. 

Itraconazole is a triazole antifungal causing side-effects, such as nausea, abdominal pain, dizziness and headache. Itraconazole does not lead to palpitations however, it may lead to heart failure and hence itraconazole is administered with caution to patients at risk of heart failure. 

Pharmacology Fluconazole, a synthetic broad spectrum bis-triazole antifungal agent, is a highly selective inhibitor of fungal cytochrome P450 and sterol C-14 alpha-demethylation. 

Pharmacology Itraconazole is a synthetic triazole antifungal agent. In vitro, itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. 

TRIAZOLE ANTIFUNGALS ITRACONAZOLE (SPORANOX ), FLUCONAZOLE (DIFLUCAN ), VORICONAZOLE (VFEND ), AND FOSFLUCONAZOLE (PRODIF )... 

Sabo JA and Abdel-Rahman SM. Voriconazole A new triazole antifungal. Ann Pharmacotherapy 2000 34 1032-1043. 

Mojaverian P., E. Radwanski, M.B. Affrime, M.N. Cayen, and C.C. Lin (1994). Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration. Antimicrobial Agents and Chemotherapy 38 2758-2762. 

It is a triazole antifungal drug closely related to ketoconazole and is meant for oral use. It is very effective in a wide range... 

Class Synthetic, broad-spectrum bis-triazole antifungal agent with activity against Cryptococcus neoformans md Candida species ... 

Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. In uence of concomitant food intake on the oral absorption oftwo triazole antifungal agents, itraconazole and uconSzra>L Clin Pharmacol, 1994 ... 

Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs 2000 9(3) 593-605. 

Koltin, Y. Hitchcock, C. (1997) The search for new triazole antifungal agents. Curr Opin Chem Biol, 1,176-182. 

In more advanced esophageal disease, oral azoles may be ineffective. Until recently, intravenous amphotericin B deoxycholate has been the alternative for patients with endoscopically proven disease who have failed fluconazole or itraconazole therapy.22 2" Moderate disease may be treated adequately with low- to moderate-dose amphotericin B for 10 days, although higher doses may be necessary for patients with AIDS or advanced disease. " Voriconzole, a new triazole antifungal available in both oral and intravenous preparations, produces comparable clinical response to fluconazole. Voriconazole has been associated with more side effects and multiple pharmacokinetic drug interactions. " ... 

Johnson LB, Kauffman CA. Voriconazole A new triazole antifungal agent. Clin Infect Dis 2003 36 630-637. 

Itraconazole is a triazole antifungal agent that inhibits the C-demethylation step in the synthesis of ergosterol, which is a vital component of fungal cell membranes. Injection used in treatment of aspergillosis, blastomycosis, histoplasmosis, and the empiric treatment of febrile neutropenic patients with suspected fungal infections. Capsules used in treatment of asper-gillosis, blastomycosis, histoplasmosis, and... 

---